The prevalence of interstitial lung disease (ILD) across connective tissue disorders (CTDs) and its persistent standing as a leading cause of death in patients with CTDs challenge rheumatologists to ...
Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments ...
Please provide your email address to receive an email when new articles are posted on . Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with ...
Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...
The FDA has approved YUTREPIA™ (treprostinil) inhalation powder, developed by Liquidia Corporation, as a treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...
The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...
The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.
Here are the top 5 most-read pulmonary fibrosis articles of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback